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Aims: Investigate efﬁcacy and tolerability of intensifying diabetes treatment with once-
or twice-daily biphasic insulin aspart 30 (BIAsp 30) added to sitagliptin, and twice-daily
BIAsp 30 without sitagliptin in patients with type 2 diabetes (T2D) inadequately controlled
on sitagliptin.
Methods: Open-label, three-arm, 24-week trial; 582 insulin-naïve patients were randomized
to twice-daily BIAsp 30+ sitagliptin (BIAsp BID+Sit), once-daily BIAsp 30+ sitagliptin (BIAsp
QD+Sit) or twice-daily BIAsp 30 without sitagliptin (BIAsp BID), all with metformin.
Results: After 24 weeks, HbA1c reduction (%) was superior with BIAsp BID+Sit vs. BIAsp
QD+Sit (BIAsp BID+Sit minus BIAsp QD+Sit difference: −0.36 [95% CI –0.54; –0.17], P<0.001)
Sitagliptin
Type 2 diabetes
Randomized trial
andBIAspBID (BIAspBIDminusBIAspBID+Sit difference: 0.24 [0.06; 0.43], P=0.01). Observed
ﬁnal HbA1c values were 6.9%, 7.2% and 7.1% (baseline 8.4%), and 59.8%, 46.5% and 49.7%
of patients achieved HbA1c <7.0%, respectively. Conﬁrmed hypoglycaemia was lower with
BIAsp QD+Sit vs. BIAsp BID (P=0.015); rate: 1.17 (BIAsp QD+Sit), 1.50 (BIAsp BID+Sit) and
2.24 (BIAsp BID) episodes/patient-year. Difference in bodyweight change favoured BIAspQD+Sit vs. both BID groups (P<0.001).
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Conclusions: Adding BIAsp 30 to patients with T2D poorly controlled with sitagliptin and
metformin is efﬁcacious and well tolerated; however, while BIAsp BID+Sit showed superior
glycaemic control, BIAsp QD+Sit had a lower rate of hypoglycaemia and showed no weight
gain.
© 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd.
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f. Introduction
reatment of patients with type 2 diabetes (T2D) aims to
educe insulin resistance and enhance beta-cell secretion
hrough lifestyle modiﬁcation and use of metformin, fol-
owed by the combination of other oral antidiabetic drugs
OADs). Nevertheless, due to the progressive deterioration
n glycaemic control, insulin therapy is often required to
chieve glycaemic goals [1]. Lowering glucose levels to the
ecommended HbA1c level <7.0% is associated with reduction
n microvascular complications and, if achieved in a timely
anner after diagnosis, may also improve macrovascular out-
omes [1].
Sitagliptin, a widely used, highly selective oral dipeptidyl
eptidase-4 (DPP-4) inhibitor, can be used in dual or triple
herapy when glycaemic control is not attained with met-
ormin [1,2]. Although DPP-4 inhibitors are weight-neutral
nd have a low hypoglycaemia risk, they are associated with
odest glucose-lowering activity (HbA1c reduction 0.5–0.9%)
3,4]. In a head-to-head comparison, signiﬁcantly better gly-
aemic control was achieved with insulin glargine versus
itagliptin, both with metformin, in insulin-naïve patients
ith T2D, although symptomatic hypoglycaemia was also
igniﬁcantly greater with this insulin-based regimen [5]. In
nsulin-naïve patients with T2D, improved glycaemic control
as also been demonstrated when starting insulin detemir
n combination with sitagliptin [6], and when adding insulin
largine to patients uncontrolled on metformin and DPP-4
nhibitors [7]. Despite these ﬁndings, there is no clear guid-
nce on whether to withdraw DPP-4 inhibitors and add insulin
herapy, or to combine these treatments when intensiﬁcation
s required in patients with poor glycaemic control on met-
ormin.
Premixed insulin or basal insulin are often considered
rst-line therapy options for patients with T2D requiring
nsulin treatment [8]. Biphasic insulin aspart 30 (BIAsp 30)
s a premixed insulin containing soluble insulin aspart and
rotamine-crystallized insulin aspart in a 30/70 ratio, thus
roviding prandial and basal glucose coverage, respectively,
hat can be administered once, twice or three-times daily.
dding BIAsp 30 has demonstrated signiﬁcant improve-
ents in glycaemic control versus OADs alone in poorly
ontrolled insulin-naïve patients with T2D [9–11]; however,
linical data on the combination of premixed insulins and
itagliptin are limited. The Sit2Mix trial aimed to investigate
fﬁcacy and tolerability of intensifying diabetes treatment
ith once- or twice-daily BIAsp 30 by either adding BIAsp 30o sitagliptin or substituting BIAsp 30 for sitagliptin in patients
ith T2D inadequately controlled on sitagliptin and met-
ormin.2. Materials and methods
2.1. Study protocol
Sit2Mix was a randomized, open-label, three-arm, parallel-
group stratiﬁed, multicentre trial conducted in Argentina,
Australia, Brazil, Greece, India, Korea, Malaysia, Portugal,
Thailand and Turkey between 2012 and 2013. A 2-week
screening period was followed by a 24-week treatment period
during which patients were randomized (1:1:1) to BIAsp 30
(NovoMix 30, Novo Nordisk, Bagsværd, Denmark) adminis-
tered twice daily + sitagliptin+metformin (BIAsp BID+Sit),
BIAsp 30 administered once daily + sitagliptin+metformin
(BIAsp QD+Sit), or BIAsp 30 administered twice
daily +metformin but without sitagliptin (BIAsp BID). Par-
ticipants were stratiﬁed according to prior OAD treatment
besides sitagliptin and metformin. All other OADs were
discontinued at randomization. The trial was conducted
in compliance with Good Clinical Practice, local regulatory
requirements and the Declaration of Helsinki.
2.2. Participants
Participants were eligible for inclusion if diagnosed with T2D
for ≥6 months before the study, ≥18 years of age, HbA1c
7.0–10.0% and BMI ≤40.0 kg/m2. Patients were required to be
insulin-naïve (short-term insulin use due to intermittent ill-
ness of ≤14 days allowed) and stable on treatment with a
total daily dose of at least 1000mg of metformin (± addi-
tional OADs) unchanged for ≥3 months prior to the study and
treatment with ≥100mg sitagliptin/day for ≥3 months before
study; also to be able and willing to (1) administer subcuta-
neous injections daily, (2) eat at least two main meals daily
and (3) perform self-measured blood glucose (SMPG) mea-
surements. Exclusion criteria included: thiazolidinedione or
glucagon-like-peptide-1 treatmentwithin the 3months before
the study; cardiac disease within the last 6 months (deﬁned
as decompensated heart failure New York Heart Association
class III or IV); unstable angina pectoris; myocardial infarc-
tion; severe hypertension (systolic blood pressure ≥180mmHg
or diastolic blood pressure ≥100mmHg); change in dose of
any systemic treatment with products which, in the inves-
tigator’s opinion, could interfere with glucose metabolism;
clinically signiﬁcant diseaseswhich, in the investigator’s opin-
ion, may confound the results of the trial or pose additional
risk in administering trial product(s); impaired hepatic func-
 
Open access under CC BY-NC-ND license.tion (aspartate aminotransferase or alanine aminotransferase
>2.5 times upper normal range); impaired renal function
(serum creatinine levels ≥133mol/L [males], ≥124mol/L
[females] or estimated creatinine clearance below 60mL/min).
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Withdrawal was at the discretion of the investigator or if non-
compliance was reported.
2.3. Treatment regimen and dosing
All participants receiving BIAsp 30 had their insulin dose
titrated by the investigator in accordance with titration guide-
lines [12]. Starting dose for BIAsp 30 was 6U pre-breakfast and
6U pre-dinner in the BID groups, and 12U pre-dinner in the
QD group. The BIAsp 30 dose was adjusted according to SMPG
measurements taken on any 3 days in the week prior to a
site visit/phone contact. This was conducted weekly for the
ﬁrst 6 weeks, and every second week thereafter. BIAsp 30 dose
was adjusted by –2U if pre-meal SMPG was <4.4mmol/L, 0U
if 4.4–6.1mmol/L, +2U if 6.2–7.8mmol/L, +4U if 7.9–10mmol/L
and +6U if >10mmol/L. All participants received a stable dose
of metformin 1000mg/day. In the BIAsp 30+ sitagliptin arms,
the dose of sitagliptin was 100mg/day.
2.4. Endpoints
Theprimary endpointwas change frombaseline inHbA1c after
24 weeks of treatment. Secondary efﬁcacy endpoints included
the proportion of subjects achieving HbA1c <7.0%, and the pro-
portion achieving HbA1c <7.0% without hypoglycaemia (any
symptomatic hypoglycaemia with a plasma glucose value
≤3.9mmol/L or any single plasma glucose value <3.1mmol/L
in the last 3 months of treatment), change from baseline
in fasting plasma glucose (FPG), total daily insulin dose and
7-point self-measured capillary SMPG proﬁles. Safety end-
points included adverse events (AEs), changes from baseline
in bodyweight, daytime and nocturnal treatment-emergent
hypoglycaemic episodes, physical examination, vital signs,
and changes in haematology and biochemistry measure-
ments. Laboratory analyses were performed by a central
laboratory. Conﬁrmed hypoglycaemia was deﬁned post hoc
and comprised all episodes with a plasma glucose measure-
ment <3.1mmol/L (regardless of symptoms) and any episodes
considered severe (requiring third-party assistance). Noctur-
nal hypoglycaemia was deemed to occur if the episode took
place between 00:01 and 05:59h (inclusive). Other endpoints
included the change from baseline in treatment satisfaction
using the self-reported Treatment Related Impact Measure –
Diabetes (TRIM-D) [13] and a general health-economic anal-
ysis of the average cost related to each treatment regimen
(costs basedondrugprices from13September 2013 fromMIMS
database).
2.5. Statistical analysis
Efﬁcacy and safety endpoints were analyzed using the full
analysis dataset and safety analysis dataset, respectively.
All analyses consisted of pair-wise two-sided tests with 5%
signiﬁcance level. Missing values were imputed using last
observation carried forward. Sample sizewas based on change
in primary endpoint and a clinically relevant treatment dif-
ference of 0.4%; a minimum sample size of 573 was required
to meet the primary objective with 90% power. Normal linear
regressionmodelswith treatment, strata and regionas factors,
and relevant baseline measurements as covariate were used9 ( 2 0 1 5 ) 370–376
for analyses of change in HbA1c, FPG, bodyweight and TRIM-
D scores. Analysis of 7-point SMPG proﬁles was conducted
using a mixed-effects model with treatment, time, interac-
tion between treatment and time, strata and region as ﬁxed
factors and subject as random. Responder analyses were ana-
lyzed based on a logistic regression model using treatment,
strata and region as factors, and baseline HbA1c as covari-
ate. Hypoglycaemia was analyzed using a negative binomial
regression model with treatment, strata and region as factors,
and the logarithm of the time period for which a hypogly-
caemic episode was considered treatment-emergent as offset.
SAS version 9.3 was used to perform the analyses and all P-
values <0.05 were considered statistically signiﬁcant.
3. Results
3.1. Study population
804 participants were screened, of which 582 were random-
ized (BIAsp BID+Sit, n=195; BIAsp QD+Sit, n=193; BIAsp BID,
n=194) and 575 exposed to treatment. Overall, 46 participants
withdrew from the trial: 13 in the BIAsp BID+Sit group, 12 in
BIAsp QD+Sit and 21 in BIAsp BID (Fig. 1). Baseline charac-
teristics were broadly comparable between groups, although
gender distribution (male vs. female) varied slightly: 60% vs.
40% in the BIAsp BID group and 50% vs. 50% in the other two
groups (Table 1). Baseline HbA1c in all groups was 8.4±0.8%
and approximately 70% of participants in each group were
receiving OADs before the study. At baseline, 2.6–6.2% of
patients across the three groups experienced nephropathy,
10.8–13.5% neuropathy, 7.7–9.3% retinopathy and 1.5–6.2%
macroangiopathy.
3.2. Glycaemic control
Observed ﬁnal HbA1c values after 24 weeks were 6.9%, 7.2%
and 7.1% for BIAsp BID+Sit, BIAsp QD+Sit and BIAsp BID,
respectively. Estimated HbA1c change (%) was statistically
superior with BIAsp BID+Sit versus BIAsp QD+Sit (−1.51 vs.
−1.15, difference: −0.36 [95% CI −0.54; −0.17], P<0.001) and
versus BIAsp BID (−1.27 vs. −1.51, difference: 0.24, [95% CI
0.06; 0.43], P=0.01) (Fig. 2). HbA1c change was not signiﬁcantly
different between BIAsp QD+Sit and BIAsp BID (difference
−0.11 [95% CI −0.30; 0.07], P=0.231). There was a comparable
FPG reduction across all treatment arms (ﬁnal observed mean
value: 7.0mmol/L). After 24 weeks, 7-point SMPG (mmol/L)
reported in the BIAsp BID+Sit arm was signiﬁcantly lower
versus the BIAsp QD+Sit arm 90 min after breakfast (differ-
ence: −1.07 [95% CI −1.65; −0.50]), before lunch (difference:
−1.12 [95% CI −1.56; −0.67]), 90 min after lunch (difference:
−1.29 [95% CI −1.81; −0.78]) and before dinner (difference:
−1.25 [95% CI −1.74; −0.76]). A similar trend was observed for
the comparison between BIAsp BID and BIAsp QD+Sit, but
the BID groups were not signiﬁcantly different to each other
(Fig. 3).The proportion of HbA1c responders (<7.0%) was 59.8%
with BIAsp BID+Sit, 46.5% with BIAsp QD+Sit and 49.7% with
BIAsp BID. The odds of reaching HbA1c <7.0% with BIAsp
BID+Sit were signiﬁcantly higher versus BIAsp BID (BIAsp
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Fig. 1 – Participant ﬂow from screening to study completion. AE, adverse event; BID, twice daily; BIAsp, biphasic insulin
a lysis
B
P
P
t
t
H
B
T
n
B
b
1
o
i
s
Q
sspart; FAS, full analysis set; QD, once daily; SAS, safety ana
ID vs. BIASp BID+Sit odds ratio [OR] 0.60 [95% CI 0.39; 0.93],
= 0.022) and vs. BIAsp QD+Sit (OR 1.85 [95% CI 1.20; 2.85],
= 0.005); however, as observed with the primary endpoint,
he BIAsp QD+Sit group was not signiﬁcantly different versus
he BIAsp BID group. The proportion of responders achieving
bA1c <7.0% without hypoglycaemia was 41.5% with BIAsp
ID+Sit, 39.2% with BIAsp QD+Sit and 27.9% with BIAsp BID.
he odds for reaching target without hypoglycaemia were sig-
iﬁcantly higher with BIAsp BID+Sit versus BIAsp BID (BIASp
ID vs. BIAsp BID+Sit OR 0.48 [95% CI 0.30; 0.76], P=0.002),
ut were not signiﬁcantly different versus BIAsp QD+Sit (OR
.13 [95% CI 0.73; 1.75], P=0.595). In contrast to the trend
bserved with the primary endpoint, the odds for reach-
ng target without hypoglycaemia with BIAsp QD+Sit were
igniﬁcantly higher versus BIAsp BID (BIASp BID vs. BIASp
D+Sit OR 0.54 [95% CI 0.34; 0.86], P=0.009) by the end of the
tudy.
Table 1 – Baseline characteristics of the Sit2Mix trial.
BIAsp BID+Sit BIAs
Number of subjects 195 193
Age, years 56.3 (10.2) 55
Sex, % (M/F) 48.2/51.8 49
Bodyweight, kg 78.3 (16.1) 77
BMI, kg/m2 29.4 (4.5) 29
HbA1c, % 8.4 (0.8) 8
FPG, mmol/L 9.3 (2.8) 8
Strata, %
+OADs 69.7 69
−OADs 30.3 30
Data are mean (SD).
BID, twice daily; BIAsp, biphasic insulin aspart; FPG, fasting plasma glucosset; Sit, sitagliptin.
3.3. Safety
Overall conﬁrmed hypoglycaemia rates were 1.17, 1.50 and
2.24 episodes/patient-year in the BIAsp QD+Sit, BIAsp
BID+Sit and BIAsp BID groups, respectively (Table 2). The
rate of conﬁrmed hypoglycaemic episodes was signiﬁcantly
lower in the BIAsp QD+Sit group versus the BIAsp BID group
(BIAsp BID vs. BIAsp QD+Sit rate ratio 1.84 [95% CI 1.12;
3.01], P=0.015), but there was no signiﬁcant difference versus
the BIAsp BID+Sit group or between the two BID groups.
Too few severe hypoglycaemia episodes were reported for
statistical analysis. No signiﬁcant differences in nocturnal
hypoglycaemia were reported.
The proportion of patients who experienced treatment-
emergent AEs was similar across groups: 44.6% with BIAsp
BID+Sit, 47.4% with BIAsp QD+Sit and 50.0% with BIAsp
BID, with corresponding event rates of 209.9, 281.2 and 262.2
p QD+Sit BIAsp BID Total
194 582
.7 (10.4) 54.8 (9.5) 55.6 (10.0)
.7/50.3 57.2/42.8 51.7/48.3
.5 (16.8) 79.4 (15.8) 78.4 (16.2)
.4 (5.0) 29.3 (4.3) 29.4 (4.6)
.4 (0.8) 8.4 (0.8) 8.4 (0.8)
.7 (2.7) 8.9 (2.2) 9.0 (2.6)
.9 67.5 69.1
.1 32.5 30.9
e; OAD, oral antidiabetic drug; QD, once daily; Sit, sitagliptin.
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Table 2 – Rates of conﬁrmed hypoglycaemia after 24 weeks’ treatment with BIAsp BID+Sit, BIAsp QD+Sit and BIAsp BID.
BIAsp BID+Sit BIAsp QD+Sit BIAsp BID
N % E R N % E R N % E R
Conﬁrmed 50 25.9 129 1.50 37 19.5 100 1.17 70 36.5 186 2.24
Severe 1 0.5 1 0.01 2 1.1 6 0.07 1 0.5 1 0.01
Minor 50 25.9 128 1.49 36 18.9 94 1.10 70 36.5 185 2.23
Nocturnal severe 0 – – – 1 0.5 3 0.04 0 – – –
Nocturnal minor 8 4.1 14 0.16 9 4.7 23 0.27 11 5.7 21 0.25
Post hoc deﬁned endpoint conﬁrmed hypoglycaemia comprised episodes with a plasma glucose measurement <3.1mmol/L (regardless of
symptoms) and severe episodes (requiring assistance from another person). A nocturnal hypoglycaemic episode had a time of onset between
00:01 and 05:59h (both included).
spart
bject%, percentage of subjects; BID, twice daily; BIAsp, biphasic insulin a
subjects with at least one episode; QD, once daily; R, episodes per su
events/100 subject exposure-years, respectively. AEs reported
in ≥5% of the study population included nasopharyngitis
(4.2–5.7%), inﬂuenza (2.6–5.7%), headache (3.6–5.7%) and diar-
rhoea (0.5–5.3%). 21 serious adverse events were reported,
of which six (all related to hypoglycaemia) were possi-
bly/probably related to trial treatment.
3.4. Change in bodyweight, insulin dose and
treatment satisfaction
After 24 weeks, mean change in bodyweight from baseline
was +1.4 kg in the BIAsp BID+Sit group (difference vs. BIAsp
QD+Sit: 1.51 [95% CI 0.82; 2.21], P<0.001), +2.1 kg for BIAsp
BID (difference vs. BIAsp QD+Sit: 2.19 [95% CI 1.49; 2.89],
P<0.001) and −0.1 kg for BIAsp QD+Sit. No signiﬁcant differ-
ence was reported between the two BID groups. Final total
daily dose was 0.66U/kg, 0.72U/kg and 0.39U/kg, respectively,
from a baseline of 0.16U/kg. In the BID groups, the morning
dose increased from0.08U/kg to 0.35U/kg (BIAsp BID+Sit) and
0.39U/kg (BIAsp BID), while the evening dose increased from
0.08U/kg to 0.31U/kg (BIAsp BID+Sit) and 0.34U/kg (BIAsp
BID).
Fig. 2 – Change in HbA1c after 24 weeks’ treatment with
BIAsp BID+Sit, BIAsp QD+Sit and BIAsp BID. BID, twice
daily; BIAsp, biphasic insulin aspart; CI, conﬁdence
interval; QD, once daily; Sit, sitagliptin.; E, number of episodes; FPG, fasting plasma glucose; N, number of
exposure-year; Sit, sitagliptin.
There were no signiﬁcant differences in TRIM-D scores
among the treatment groups. The overall TRIM-D score after
24 weeks was 76.64, 77.79 and 76.46 in the BIAsp BID+Sit,
BIAsp QD+Sit and BIAsp BID groups, respectively, with base-
line values of 70.28, 72.40 and 69.30.
3.5. Costs
Average total medicine costs in each arm (in subjects exposed
≥20 weeks) were GBP 345.7 for BIAsp BID+Sit, GBP 287.9 for
BIAsp QD+Sit and GBP 160.0 for BIAsp BID. No further cost
analyses were conducted.
4. Discussion
Clinicians need to balance risks, costs and beneﬁts of differ-
ent treatment approacheswhen choosing a suitable treatment
plan for patients with diabetes. Moreover, individual circum-
stances should be considered, i.e. age, comorbidities, baseline
HbA1c, ability to adhere to complex regimens, to optimize
outcomes when choosing an antihyperglycaemic strategy [2].
Sit2Mix included a relatively homogenous population at base-
line and investigated three distinct intensiﬁcation regimens
Fig. 3 – 7-point SMPG proﬁles at baseline and end of trial.
*Signiﬁcant treatment difference between BIAsp BID+Sit
vs. BIAsp QD+Sit and BIAsp QD+Sit vs. BIAsp BID. BID,
twice daily; BIAsp, biphasic insulin aspart; QD, once daily;
Sit, sitagliptin; SMPG, self-measured blood glucose; BL,
baseline.
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n patients with T2D failing to be controlled on sitagliptin
nd metformin in combination with other OADs. All regi-
ens were efﬁcacious and well tolerated after 24 weeks of
reatment, but each presented a different proﬁle in terms
f treatment beneﬁts and risks. The BIAsp BID+Sit regimen
howed greater improvement in glycaemic control versus
IAsp QD+Sit and BIAsp BID. Nevertheless, HbA1c change
n both the BIAsp QD+Sit and BIAsp BID groups was ≥1.0%
nd a change of this magnitude is associated with reduced
isk for microvascular and macrovascular complications [14].
he improvement observed in mean SMPG after breakfast and
unch, and before lunch and dinner, in the BID groups is likely
reﬂection of the different dose-administration timings with
ID and QD regimens (dosing before breakfast and dinner vs.
osing before dinner only, respectively). Although a greater
roportion of patients achieved the recommended HbA1c tar-
et <7.0% in the BIAsp BID+Sit group (approximately 60%)
ersus the other groups, this trend was not maintained upon
xamination of those patients who achieved target without
ypoglycaemia. For this endpoint, the proportions of respon-
ers in the BIAsp BID+Sit and BIAsp QD+Sit groups were
omparable (39–41.5%), yet the proportion in theQD groupwas
reater than in the BIAsp BID group. The driving factor of this
nding is likely the reported reduction in hypoglycaemia rate
n the BIAsp QD+Sit group versus the BIAsp BID group. Also
oteworthy, the change in bodyweightwas signiﬁcantly less in
he BIAsp QD+Sit group versus the BID groups. Furthermore,
ccording to TRIM-D questionnaire results, the impact on the
atient is broadly similar regardless of treatment, suggesting
hat changing to a BIAsp 30-based regimen in these patients
s not burdensome, and compliance and convenience are not
ompromised.
Our ﬁndings support different intensiﬁcation regimens
ith BIAsp 30 that could be used in the treatment continuum
f T2D. It should be noted, however, that although other
egimens can be considered when starting insulin therapy
.g. basal insulin [1,2], our ﬁndings are relevant for those
atients where premix insulin has been selected as the
tarting insulin of choice. Given the limited guidance from
he ADA/EASD consensus algorithm regarding withdrawing
PP-4 inhibitors or adding on insulin therapy when inten-
iﬁcation is required, we consider the presented data to be
n important source of evidence to help guide clinicians and
upport individualized decisions based on endpoints that are
ertinent to a patient’s wellbeing and management of their
iabetes. Adding BIAsp 30 BID to sitagliptin plus metformin
ould be the most effective choice (versus the other groups
tudied here) if targeting glycaemic control was the main
oncern; however, relative risk of hypoglycaemia and weight
ain are also greater with this regimen and should be taken
nto consideration, along with patients’ circumstances, when
evising a treatment plan. Conversely, our data suggest that
atients concerned about weight gain and/or those more
rone to hypoglycaemia may beneﬁt more from adding BIAsp
D to sitagliptin, although the extent of improvement in
bA1c is not as considerable versus a BID BIAsp regimen with
r without sitagliptin. Discontinuing sitagliptin followed by
nitiation of BIAsp BID (while continuing metformin) had
imilar efﬁcacy, but a signiﬁcantly greater change in body-
eight, versus adding BIAsp QD to sitagliptin and metformin.( 2 0 1 5 ) 370–376 375
The treatment costs associated with discontinuing sitagliptin
and starting BIAsp BD were 1.8- and 2.1-fold lower versus
the BIAsp QD+Sit and BIAsp BID+Sit groups, respectively,
thus the impact of costs also needs to be weighed against the
clinical beneﬁts and risks when comparing regimens.
To our knowledge, this is the ﬁrst randomized, global study
evaluating the combination of BIAsp 30 and sitagliptin, and
the substitution of sitagliptin with BIAsp 30, thus provid-
ing valuable evidence for clinicians who would consider this
approach for poorly controlled, insulin-naïve patients with
T2D. However, the study does have limitations, including the
absence of a sitagliptin-only control group and a restricted
cost-analysis, which only considers the cost of the medicine
itself and excludes costs associated with general diabetes
management and complications. In addition, too few severe
hypoglycaemic episodes were reported to allow for statistical
analysis, which was also the case in the ﬁndings from Gar-
ber and colleagues who, in an observational study, reported
few major hypoglycaemic episodes and no major nocturnal
hypoglycaemic episodes during intensiﬁcation of once-daily
BIAsp 30 to twice- or three-times daily regimens [15]. Further-
more, our ﬁndings are speciﬁc to sitagliptin and BIAsp 30, so
results cannot be extrapolated to other DPP-4 inhibitors or
different ratio premix insulins.
In conclusion, intensiﬁcationwithBIAsp30 inpatientswith
T2D inadequately controlled with sitagliptin and metformin
was shown to be efﬁcacious and well tolerated using three
distinct intensiﬁcation regimens. The balance of beneﬁts vs.
risks was different for each of the studied regimens, provid-
ing evidence-supported therapy options for clinicians when
tailoring a treatment plan for patients poorly controlled on
sitagliptin and metformin.
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